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PPeripheral Vascular Disease
Plasma Levels of Soluble Tie2
and Vascular Endothelial Growth Factor
Distinguish Critical Limb Ischemia From Intermittent
Claudication in Patients With Peripheral Arterial Disease
Clarence M. Findley, PHD,*†‡ Robert G. Mitchell, MD,* Brian D. Duscha, MS,*
Brian H. Annex, MD,*§ Christopher D. Kontos, MD, FACC*‡
Durham, North Carolina
Objectives Our purpose was to determine whether factors that regulate angiogenesis are altered in peripheral arterial dis-
ease (PAD) and whether these factors are associated with the severity of PAD.
Background Alterations in angiogenic growth factors occur in cardiovascular disease (CVD), but whether these factors are
altered in PAD or correlate with disease severity is unknown.
Methods Plasma was collected from patients with PAD (n  46) and healthy control subjects (n  23). Peripheral arterial
disease patients included those with intermittent claudication (IC) (n  23) and critical limb ischemia (CLI) (n 
23). Plasma angiopoietin-2 (Ang2), soluble Tie2 (sTie2), vascular endothelial growth factor (VEGF), soluble VEGF
receptor 1 (sVEGFR-1), and placenta growth factor (PlGF) were measured by enzyme-linked immunoadsorbent
assay. In vitro, endothelial cells (ECs) were treated with recombinant VEGF to investigate effects on sTie2 pro-
duction.
Results Plasma concentrations of sTie2 (p  0.01), Ang2 (p  0.001), and VEGF (p  0.01), but not PlGF or sVEGFR-1,
were significantly greater in PAD patients compared with control subjects. Plasma Ang2 was significantly in-
creased in both IC and CLI compared with control subjects (p  0.0001), but there was no difference between IC
and CLI. Plasma VEGF and sTie2 were similar in control subjects and IC but were significantly increased in CLI
(p  0.001 vs. control or IC). Increased sTie2 and VEGF were independent of CVD risk factors or the ankle-
brachial index, and VEGF treatment of ECs in vitro significantly increased sTie2 shedding.
Conclusions Levels of VEGF and sTie2 are significantly increased in CLI, and sTie2 production is induced by VEGF. These pro-
teins may provide novel biomarkers for CLI, and sTie2 may be both a marker and a cause of CLI. (J Am Coll
Cardiol 2008;52:387–93) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.02.0451
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teripheral arterial disease (PAD) is characterized by ath-
rosclerosis of noncardiac vascular beds and most commonly
ffects the lower extremities. Although widely under-
ecognized, PAD is a major health problem, affecting 8 to
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007, accepted February 7, 2008.2 million individuals in the U.S. (1). The 2 major clinical
anifestations of PAD of the lower extremities are inter-
ittent claudication (IC) and critical limb ischemia (CLI),
hich have markedly different clinical outcomes (2).
See page 394
ntermittent claudication is characterized by reproducible
ain on exertion that is relieved with rest. Critical limb
schemia is the most severe form of PAD and is character-
zed by the inability of arterial blood flow to meet the
etabolic demands of resting muscle or tissue, resulting in
est pain and/or tissue necrosis, which frequently necessi-
ates amputation (3,4). Whereas annual mortality in pa-
ients with IC is only 1% to 2%, the annual risk of death in
atients with CLI is up to 20% (3,4). Therefore, early
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sTie2 and VEGF as Markers of CLI July 29, 2008:387–93identification would be expected
to provide improved treatment
options for patients with PAD.
Currently, the ankle-brachial
index (ABI) is the standard for
diagnosis of PAD, however the
correlation between ABI and se-
verity of PAD is poor (5). Aside
from the ABI, there are no other
reliable diagnostic tests for PAD.
Furthermore, the diagnosis of IC
versus CLI is purely clinical. Pa-
tients with IC and CLI can
present with virtually identical
clinical risk factors (e.g., tobacco
use, diabetes mellitus), periph-
eral hemodynamic parameters,
and degree of atherosclerotic
burden (6). Therefore, mini-
mally invasive tests or biomark-
ers to diagnose PAD and poten-
tially distinguish between IC and
CLI are needed.
In PAD, atherosclerotic arterial occlusive disease results
n tissue ischemia and varying degrees of collateral blood
essel growth (i.e., angiogenesis). The extent of collateral
lood vessel formation has the potential to affect the clinical
anifestations of PAD; thus insufficient angiogenesis may
e responsible for the different clinical presentations of
atients with IC and CLI. A number of angiogenic growth
actors and endogenous inhibitors of angiogenesis have the
otential to modulate vascular growth in PAD. Among
hese, vascular endothelial growth factor (VEGF)-A is
erhaps the most important proangiogenic factor, because it
s required for both physiological and pathological angio-
enesis (7) and even minor changes in its expression can
ead to dramatic alterations in vascular growth and remod-
ling (8). The related placenta growth factor (PlGF) binds
common receptor, VEGF receptor 1 (VEGFR-1), and
lthough it is not required for normal embryonic vascular
evelopment, it plays a critical role in pathological angio-
enesis (9). The angiopoietins are ligands for the endothe-
ial receptor Tie2 (10), and angiopoietin-2 (Ang2) is up-
egulated by VEGF (11) and in some cases has been shown
o be required for VEGF-mediated angiogenesis (12).
nterestingly, soluble forms of both VEGFR-1 and Tie2 are
roduced and secreted into the circulation, where they can
ind their respective growth factors and inhibit angiogenesis
13). Whereas soluble VEGFR-1 (sVEGFR-1) is produced
y alternative splicing of the VEGFR-1 gene (14), soluble
ie2 (sTie2) results from proteolytic cleavage of the full-
ength membrane-bound receptor (15), and both proteins
ave been implicated in the pathogenesis of cardiovascular
isease (CVD) (16,17).
For the present report, we hypothesized that differences
Abbreviations
and Acronyms
ABI  ankle-brachial index
Ang2  angiopoietin-2
CLI  critical limb
ischemia
CVD  cardiovascular
disease
HUVEC  human umbilical
vein endothelial cell
IC  intermittent
claudication
PAD  peripheral arterial
disease
PlGF  placenta growth
factor
sTie2  soluble Tie2
sVEGFR-1  soluble
vascular endothelial growth
factor receptor 1
VEGF  vascular
endothelial growth factorn expression of these angiogenic growth factors and/or their Voluble receptors might provide markers of PAD and its
ifferent clinical manifestations. To investigate this possi-
ility, plasma from control subjects and patients with IC
nd CLI was analyzed for changes in the proangiogenic
rowth factors Ang2, VEGF-A, and PlGF, along with their
oluble receptors sVEGFR-1 and sTie2, which act as
ndogenous inhibitors of angiogenesis. We found that
atients with PAD have significantly higher plasma con-
entrations of Ang2, VEGF, and sTie2 compared with
ontrol subjects, but only VEGF and sTie2 concentrations
istinguished patients with CLI from those with IC.
ethods
ubject recruitment. Subjects with PAD were recruited
onsecutively from the vascular medicine clinics at Duke
niversity Medical Center, and control subjects were re-
ruited from the vascular screening clinics if they showed no
vidence of PAD, as demonstrated by an ABI of1.0 or by
ther diagnostic testing. All patient studies were approved
y the Duke University Institutional Review Board. All
atients were over 18 years of age and able to give informed
onsent for a single 10-ml blood draw. The study popula-
ion comprised 23 control subjects without PAD and 46
atients with PAD. Peripheral arterial disease subjects
ncluded 23 patients with IC and 23 patients with CLI,
ased on the Rutherford criteria (18). Intermittent claudi-
ation patients had an ABI of 0.5 to 0.9 and exercise-
imiting claudication, and the CLI subjects were identified
y an ABI of 0.5 and the presence of a nonhealing lower
xtremity ulcer, rest pain, or gangrene. Control subjects
ere age and gender matched and were without clinical
vidence of vascular, metabolic, or neoplastic disease, based
n patient history and physical examination and routine
aboratory studies. Subjects were excluded if they had
vidence of acute coronary syndromes and/or acute decom-
ensated heart failure in the preceding 6 weeks or Child-
ugh class C liver disease. Sample size was determined
ased on 80% power to detect a significant difference in at
east 1 measured factor between control and PAD subjects
ithout distinction between IC and CLI subgroups. The
ubjects’ demographic characteristics are shown in Table 1.
ample acquisition and analysis of angiogenesis-
odulating factors. Blood was collected by venipuncture
nto EDTA-containing tubes. Whole blood samples were
laced on ice and immediately centrifuged at 2,000  g for
min at 4°C for plasma separation. Plasma was aliquoted
nd stored at 80°C. The concentrations of sTie2, VEGF-
165, Ang2, PlGF, and sVEGFR-1 were quantified using
ommercially available enzyme-linked immunoadsorbent
ssay (ELISA) kits (R&D Systems, Minneapolis, Minne-
ota) according to the manufacturer’s instructions. Assay
ensitivities, quantified as the mean minimal detectable
oncentration for each assay, were: sTie2 14 pg/ml;
EGF-A 5.0 to 9.0 pg/ml; Ang2 8.3 pg/ml; PlGF 7 pg/ml;
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July 29, 2008:387–93 sTie2 and VEGF as Markers of CLInd sVEGFR-1 3.5 pg/ml. Coefficients of variation (intra-
ssay precision) were 4% for all assays.
ell culture studies. Human umbilical vein endothelial
ells (HUVECs) were harvested from fresh umbilical
ords, phenotyped as described previously (19), and used
etween passages 2 and 6. Cells were grown in endothe-
ial growth medium (EGM)-MV (Cambrex, Walkers-
ille, Maryland) until confluent. The cells were then
hanged to serum-free medium, and triplicate samples
ere treated with vehicle or with recombinant human
EGF165 (25 ng/ml, R&D Systems) for 24 h. The
onditioned media were then collected and sTie2 con-
entration was quantified by ELISA, as described in the
receding text. Enzyme-linked immunoadsorbent assay
ata are presented as the mean  SD from triplicate
amples. Experiments were repeated on at least 3 separate
ccasions. Statistical comparisons were performed using
tudent t test, and significance was set at p  0.05.
tatistical analysis. Statistical analysis was performed us-
ng SPSS 16.0 for Windows (SPSS Inc., Chicago, Illinois).
atient demographic data were compared across all 3 groups
y analysis of variance (ANOVA) for continuous variables
ollowed by chi-square analysis to compare IC and CLI
atients. Categorical variables were compared between IC
nd CLI groups using a nonparametric chi-square test.
ategorical variables that were significantly different
etween the IC and CLI patients were controlled for
sing analysis of covariance (ANCOVA) to compare levels
f VEGF and sTie2 within the PAD cohort. Similarly,
NCOVA was used to control for the effects of differences
n ABI on VEGF and sTie2 concentrations in IC versus
LI patients. For analysis of ELISA data, which were not
ormally distributed, the data were log-transformed and
nalyzed by 1-way ANOVA followed by the Fisher least
ignificant difference test or the Student t test where
ppropriate. Graphical data are presented as the non–log-
ransformed values and are expressed as the mean  SD.
atient Demographics
Table 1 Patient Demographics
Control
(n  23) (n
Age, median (min–max), yrs 51.7 (36–72) 56.1
Male, n (%) 14 (61.2) 12
Caucasian, n (%) 13 (56.5) 15
ABI,* median (min–max) 1.09 (0.91–1.36) (n  22) 0.55 (0.48–
Diabetes mellitus 0 (0.0) 4
Smoking history, n (%) 11 (47.8) 16
Prior coronary artery disease, n (%) 3 (14.3) 9
Prior lower extremity vascular intervention 0 (0.0) 9
Hyperlipidemia (LDL 130 mg/dl) 8 (34.7) 15
Statin use 4 (17.3) 19
Hypertension 7 (30.4) 14
ACEI/ARB 2 (8.6) 8
ABI data were not available for all patients.
ABI ankle-brachial index; ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin re
DL  low-density lipoprotein.tatistical significance was set at p  0.05. iesults
aseline patient characteristics. The baseline demo-
raphic and clinical characteristics of the study population
re shown in Table 1. Comparing patients with IC and
LI, a significantly greater percentage with CLI were male,
iabetic, hypertensive, and had a history of smoking and
eripheral vascular intervention (Table 1). There were no
ignificant differences in the use of cardiovascular medica-
ions (angiotensin-converting enzyme inhibitor/angiotensin
eceptor blocker or statins) between patients with IC and
hose with CLI (Table 1).
nalysis of angiogenic growth factors and inhibitors in
AD and control subjects. Plasma concentrations of the 5
ifferent factors were analyzed in control subjects versus all
AD patients combined. Plasma concentrations of
VEGFR-1 and PlGF were not significantly different in PAD
atients compared with control subjects (Figs. 1A and 1B).
owever, levels of Ang2, VEGF, and sTie2 were significantly
igher in PAD patients (Figs. 1C to 1E).
nalysis of angiogenic growth factors and inhibitors
ithin PAD groups (IC vs. CLI). Visually, there was a
tepwise increase in plasma Ang2 expression from control
ubjects to patients with IC to patients with CLI (Fig. 2A).
lthough Ang2 concentrations were significantly greater in
oth PAD groups compared with controls, Ang2 expression
as not statistically different in patients with IC and those
ith CLI (Fig. 2A). In contrast, plasma VEGF expression
as not significantly increased in IC patients compared with
ontrol subjects (Fig. 2B). However, plasma VEGF expres-
ion was significantly higher in patients with CLI compared
ith those with IC (Fig. 2B). Similarly, plasma sTie2 levels
ere not significantly different in patients with IC com-
ared with controls, but they were significantly higher in
LI patients compared with either IC patients or control
ubjects (Fig. 2C). Mean sTie2 levels in the 3 groups were
0.6  1.8 ng/ml, 22.8  1.5 ng/ml, and 32.1  1.4 ng/ml
CLI
(n  23)
p Value
(ANOVA)
p Value
(Chi-Square IC vs. CLI)
9) 62.3 (29–90) 0.02 0.25
15 (65.2) 0.001
17 (74.1) 0.13
(n  21) 0.39 (0.08–0.53) (n  17) 0.001 0.001
9 (42.9) 0.003
18 (78.2) 0.001
17 (74.1) 0.37
19 (82.6) 0.001
11 (47.8) 0.37
16 (69.5) 0.08
15 (65.2) 0.01
11 (47.8) 0.37
locker; ANOVA analysis of variance; CLI critical limb ischemia; IC intermittent claudication;IC
 23)
(40–6
(52.2)
(65.2)
0.86)
(17.4)
(69.5)
(39.1)
(39.1)
(65.2)
(82.6)
(60.8)
(34.8)n control, IC, and CLI patients, respectively.
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sTie2 and VEGF as Markers of CLI July 29, 2008:387–93Tie2 and VEGF concentrations are independent of
ardiovascular risk factors. Circulating concentrations of
EGF and sTie2 could be altered as a result of concomitant
VD and endothelial dysfunction. Analysis of the baseline
emographic and clinical characteristics of patients with IC
nd CLI revealed that significantly more CLI patients were
ale, diabetic, hypertensive, and had a history of smoking
Table 1). Therefore, we performed ANCOVA for each of
hese categorical variables with VEGF and sTie2 concen-
rations and found that differences in both VEGF and sTie2
etween the IC and CLI groups remained significant (p 
.001) in the present study population.
Tie2 and VEGF concentrations are independent of the
BI. The ABI values were lower within the CLI patients
han in those with IC (Table 1). However, when we
ontrolled for differences in ABI, the increased concentra-
ions of both sTie2 and VEGF in CLI versus IC patients
emained significantly different (p  0.001). These findings
emonstrate that increased levels of sTie2 and VEGF
orrelate with disease state but not with the ABI, suggesting
hat these proteins are potential markers of CLI.
nteraction between VEGF and sTie2. The finding that
Tie2 and VEGF concentrations were similarly elevated
n subjects with CLI compared with controls or those with
C suggested a potential mechanistic link between VEGF
nd sTie2. It is known that VEGF activates proteases upon
timulation of endothelial cells (7) and that sTie2 is a
roteolytic cleavage product of the full-length membrane-
ound receptor (20). Moreover, VEGF has been shown to
nduce proteolysis of the related Tie1 receptor (21). There-
ore, we stimulated HUVECs with recombinant human
EGF and analyzed cell-conditioned medium for the
resence of cleaved sTie2 by ELISA. Vascular endothelial
rowth factor induced a significant increase in sTie2 in vitro
Fig. 3), suggesting that increased sTie2 levels in CLI are a
esult of increased VEGF expression.
iscussion
eripheral arterial disease is a major health care problem in
he U.S., and the prevalence of PAD is increasing. Al-
hough the ABI is currently the gold standard for the
iagnosis of PAD, there are a number of limitations to its
se, and new diagnostic tests are needed. Because PAD is
haracterized by decreased tissue perfusion and tissue hyp-
xia, we hypothesized that concentrations of circulating
ngiogenic growth factors and/or inhibitors of angiogenesis
ould be altered in subjects with PAD and that these
actors might provide important diagnostic and therapeutic
argets in this disease. We found that plasma concentrations
f Ang2, VEGF, and sTie2 were all significantly elevated in
atients with PAD compared with control subjects. Fur-
hermore, plasma concentrations of VEGF and sTie2, but
ot Ang2, were significantly increased in patients with CLI
ompared with those with IC. Increases in VEGF and0
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Figure 1 Plasma Concentrations of Ang2,
VEGF, and sTie2 Are Increased in PAD
Plasma concentrations of sVEGFR-1 (A), PlGF (B), Ang2 (C), VEGF (D), and
sTie2 (E) were measured in control subjects (n  23) and patients with PAD (n
 46). Concentrations of sVEGFR-1 and PlGF were not significantly different
between the 2 populations; however, Ang2 (*p  0.0001), VEGF (*p  0.01),
and sTie2 (*p  0.01) were significantly greater in PAD patients. Ang2 
angiopoietin-2; PAD  peripheral arterial disease; PlGF  placenta growth fac-
tor; sTie2  soluble Tie2; sVEGFR  soluble vascular endothelial growth factor
receptor; VEGF  vascular endothelial growth factor. Tie2 in CLI patients were independent of CVD risk
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July 29, 2008:387–93 sTie2 and VEGF as Markers of CLIactors and the ABI. Moreover, VEGF was found to induce
hedding of sTie2 from endothelial cells in vitro, suggesting
potential mechanistic link between these 2 proteins.
aken together, these findings suggest that sTie2 and
EGF may provide novel biomarkers for PAD in general
nd CLI more specifically. These results have implications
or understanding the pathophysiology and potentially im-
roving the diagnosis and treatment of PAD.
Despite its increasing prevalence, PAD continues to be
linically under-recognized. Recent data indicate that a
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Figure 2 Plasma VEGF and sTie2 Levels Distinguish Patients
With CLI From Control Subjects or Patients With IC
Plasma concentrations of Ang2, VEGF, and sTie2 were measured and com-
pared in control subjects (n  23) and patients with IC (n  23) or CLI (n 
23). (A) Plasma concentrations of Ang2 were significantly increased in both IC
(**p  0.01) and CLI (***p  0.0001) patients compared with control sub-
jects, but there was no significant difference between IC and CLI. (B) Vascular
endothelial growth factor levels were significantly increased in CLI patients
compared with control subjects (**p  0.01) and IC (*p  0.05), but there
was no difference between IC and control subjects. (C) sTie2 concentrations
were significantly greater in CLI patients compared with control subjects
(***p  0.0001) and IC (***p  0.0001), but there was no difference
between IC and control subjects. CLI  critical limb ischemia; IC  intermittent
claudication; other abbreviations as in Figure 1.ignificant percentage of patients with PAD are asymptom-tic or present with atypical symptoms (22). Moreover,
atients with PAD frequently have concomitant coronary
rtery disease, and their risk of cardiovascular events is
ignificantly higher than in patients without PAD. As a
esult, the early identification of PAD is of paramount
mportance, because it would lead to earlier and more
ggressive cardiovascular risk factor modification. The iden-
ification of novel biomarkers of PAD would aid substan-
ially in this effort. To this end, Wilson et al. (23) recently
sed an unbiased proteomic approach to demonstrate that
2-microglobulin (2M) is up-regulated in the serum of
atients with PAD. 2-microglobulin is a component of the
lass I major histocompatibility complex and is present on
irtually all cell membranes, and although the mechanism of
ts increased release is not understood, its identification as a
otential biomarker of PAD represents an important step
orward in the diagnosis and management of this disease
24). Proteomic techniques such as the mass spectroscopy
pproach used by Wilson et al. (23) provide an attractive
eans of identifying potential protein biomarkers. How-
ver, an important limitation of these approaches is that
hey can detect only a small subset of the total serum
roteome. Many serum proteins are masked by albumin or
ther abundant proteins, and a number of proteins of
nterest, including most cytokines and growth factors, are
resent in serum at concentrations that are below the level
f detection with these techniques. Therefore, the
ypothesis-driven targeted approach used in the present
tudy provides an important complement in investigating
otential biomarkers for PAD.
Peripheral arterial disease is characterized by tissue isch-
mia, and the resulting tissue hypoxia provides a potent
ngiogenic stimulus. Therefore, PAD should result in
p-regulation of angiogenic factors in order to induce a
ompensatory angiogenic response, and VEGF, Ang2, and
VEGFR-1 are all known to be up-regulated by hypoxia in
itro (25–27). A number of studies have examined circulat-
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Figure 3 sTie2 Production Is Induced by VEGF In Vitro
Human umbilical vein endothelial cells were stimulated with VEGF-A165 (25
ng/ml) for 24 h. Concentration of sTie2 in the cell-conditioned medium was
quantified by enzyme-linked immunoadsorbent assay. Vascular endothelial
growth factor treatment significantly increased release of sTie2 (*p  0.01).
Abbreviations as in Figure 1.
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sTie2 and VEGF as Markers of CLI July 29, 2008:387–93ng levels of angiogenesis-modulating proteins in the setting
f CVD or in patients with CVD risk factors, such as
ypertension and diabetes mellitus. Similar to our results,
lasma concentrations of VEGF, Ang2, and sTie2 have
een found to be increased the setting of coronary artery
isease, acute coronary syndromes (17,28), and hyperten-
ion (29). Increased VEGF and Ang2 have also been
emonstrated in the setting of diabetes (30), although there
ppear to be no data on sTie2 levels in diabetics. In the
ontext of PAD, only VEGF and sVEGFR-1 have been
tudied previously, and, consistent with our findings, plasma
EGF concentrations were found to be higher in patients
ith PAD compared with controls (31–33). Also in agree-
ent with our results, circulating levels of sVEGFR-1 were
ot increased in patients with PAD but were either un-
hanged (31,33) or reduced (32) compared with controls.
mportantly, after controlling for major demographic and
ardiovascular risk factors in the present study, the differ-
nces in circulating sTie2 and VEGF levels in CLI patients
emained significant.
Our study subdivided PAD patients by their diagnosis of
C or CLI, which have markedly different outcomes.
urrently, the diagnosis of IC versus CLI is largely clinical
nd is based on a combination of signs, symptoms, and, to
certain degree, the ABI. Our finding that VEGF and
Tie2 were significantly increased in patients with CLI
ompared to IC indicates that plasma concentrations of
hese proteins may distinguish between these two condi-
ions. To our knowledge, only one study has attempted to
orrelate expression of angiogenic proteins with severity of
AD. Makin et al. (31) examined VEGF levels in PAD
atients as a function of the ABI and found that VEGF
oncentrations did not differ in patients with ABIs above or
elow 0.52. Although that study did not classify patients
linically as having CLI, no correlation was found between
lasma VEGF concentration and the presence of rest pain
31). A critical difference in our study is that patients were
iven a clinical diagnosis of CLI that was not based on the
BI alone, since it correlates poorly with disease state.
mportantly, our data demonstrate a significant association
etween levels of sTie2 or VEGF and the clinical diagnosis
f CLI that is independent of the ABI. These findings
uggest that sTie2 and/or VEGF may provide novel bio-
arkers for this manifestation of PAD.
Whereas VEGF is likely up-regulated as a compensatory
esponse to ischemia in PAD, sTie2 appears more likely to
lay a role in the pathogenesis of the disease. Although IC
nd CLI have traditionally been thought of as early versus
ate or minor versus severe variants of the same disease,
ecent evidence suggests that these manifestations of PAD
ay be caused by distinct mechanisms. In this regard, the
p-regulation of an inhibitor of angiogenesis such as sTie2
ould worsen the clinical presentation despite having a
imilar extent of vascular occlusive disease. If so, sTie2 could
erve as a target for therapeutic intervention in PAD.
urthermore, the increase in circulating levels of both iEGF and sTie2 in CLI patients suggests a mechanistic
ink between these 2 proteins. Accordingly, the present data
emonstrated that VEGF induced proteolytic cleavage and
hedding of sTie2 in vitro, and recent concomitant work
rom our laboratory has demonstrated that this process is
ediated through the phosphoinositide 3-kinase/Akt path-
ay (15). Therefore, it is possible that ischemia-induced
ncreases in VEGF expression result in dysregulated cleav-
ge of sTie2, thereby limiting the angiogenic response to
issue hypoxia in those patients with the most severe
schemia, eventually resulting in CLI.
The regulation of Tie2 cleavage and subsequent shedding
f sTie2 is poorly understood. Earlier studies have demon-
trated sTie2 in the serum of healthy individuals (20) as well
s in patients with a variety of CVDs, including congestive
eart failure, hypertension, and acute coronary syndromes
17,29,34). Moreover, in renal cell carcinoma patients,
Tie2 concentrations correlated with severity of disease and
ecreased survival (35). The present study is the first to
xamine sTie2 levels in PAD, and the correlation of sTie2
ith CLI provides important insights into this manifesta-
ion of PAD.
tudy limitations. Although a clear limitation of the cur-
ent study is the modest sample size, a unique feature of the
tudy is the analysis of subclassifications of patients with
AD (i.e., IC and CLI). Moreover, investigation of changes
n factors involved in angiogenesis provides novel insights
nto the pathophysiology of this disease and its different
anifestations. Although the present results suggest that
lasma concentrations of Ang2 are not significantly different
etween patients with IC and those with CLI, the study was
nderpowered to rule out a type II error (i.e., a false
egative) in this analysis. Therefore, assessment of larger
opulations will be necessary to confirm whether Ang2
ight also serve as a marker of CLI as well as to validate the
resent observations on sTie2 and VEGF in this popula-
ion. Furthermore, investigation of temporal changes in
hese factors in PAD populations may be clinically relevant,
nd additional studies will be needed to establish quantita-
ive values of sTie2 and/or VEGF that define CLI with
elatively high sensitivity and specificity. The targeted
ypothesis-driven approach used here to investigate changes
n angiogenesis modulatory proteins is limited in its analysis
f only a small subset of potential biomarkers of PAD.
herefore, additional unbiased proteomic approaches, as
escribed recently for the identification of 2M (23), might
ead to the identification of additional PAD biomarkers.
onclusions
he present study demonstrated that plasma levels of sTie2
nd VEGF are significantly increased in patients with PAD
nd that increases in these proteins distinguish patients with
LI from those with IC. Because the signs and symptoms
f CLI can overlap with those of other disease states,
ncluding neuropathies and venous ulcers, these results
c
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July 29, 2008:387–93 sTie2 and VEGF as Markers of CLIould have important implications for the diagnosis of CLI.
hese results also demonstrate a potential mechanistic link
etween VEGF and sTie2 in PAD, suggesting that sTie2
ay serve not only as a marker of CLI but also as a viable
arget for therapeutic intervention in this disease.
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